Brigatinib (Alunbrig)

Brigatinib at a glance

Brigatinib, with the verified brand Alunbrig, blocks a growth-signalling protein called anaplastic lymphoma kinase, or ALK. Testing the tumour for an ALK change helps the specialist decide whether this type of treatment is appropriate. A positive result is one part of that decision; previous treatment and your general health also matter.

It is normally taken once a day. The usual adult schedule begins with 90 mg daily for seven days, followed by 180 mg daily if tolerated and prescribed. The lower starting dose is an important safety step. Some people need a different dose because of side effects, interactions, or severe kidney or liver impairment.

The most important practical points are to report breathing changes immediately, attend blood tests, check blood pressure as arranged, protect your skin from sunlight, and have every new medicine checked for interactions. Being a tablet does not make brigatinib a low-risk treatment.

How brigatinib works

ALK is a protein involved in communication inside cells. In some tumours, an ALK gene rearrangement produces an abnormal signal that encourages cancer cells to grow. Brigatinib is a tyrosine kinase inhibitor: it interferes with the activity of this signalling protein. It is a targeted treatment rather than conventional chemotherapy.

The aim is to slow or control the cancer when its biology makes this approach suitable. It cannot be assumed to work equally well for every person with an ALK result. Your team follows scans, symptoms and other findings to assess what it is doing for you. Side-effect intensity does not measure how well the cancer is responding.

An ALK change identified in a tumour does not automatically mean you inherited it or that relatives have it. Ask what your particular test examined if you are unsure. Your specialist can explain whether any separate inherited-risk assessment is relevant.

How your team decides whether it is suitable

The team considers the diagnosis, tumour testing, previous medicines and their effects, the areas requiring treatment, and your ability to take and tolerate tablets. A validated ALK test is important. The specialist also considers the applicable prescribing information and alternatives without relying on the brand name alone.

Describe any history of lung inflammation, breathing problems, low oxygen, heart disease, slow pulse, high blood pressure, diabetes, liver or kidney disease, pancreatitis, muscle problems or changes in eyesight. Previous treatment-related lung inflammation deserves particular attention before starting.

Ask what benefit is being sought, when the first response assessment will take place and what would prompt a change. Treatment commonly continues while it remains helpful and tolerable; there is no single finishing date that applies to everyone. A treatment pause or lower dose may be part of managing safety rather than proof that treatment has failed.

Before treatment starts

The team reviews your medicines and obtains baseline checks. These include blood pressure and pulse, fasting blood glucose, and blood tests to assess organs and blood cells. Liver results are particularly important. Tell the team what your breathing and activity levels are normally like so that a new change can be recognised quickly.

The monitoring plan includes creatine phosphokinase, often shortened to CPK, a marker that can rise with muscle injury, and pancreatic enzymes called amylase and lipase. These blood tests can reveal changes before you feel ill. Your team decides the schedule and whether other investigations are needed.

Pregnancy status should be checked before treatment when pregnancy is possible. Arrange suitable contraception before the first tablet, and discuss fertility preservation if future parenthood matters to you. Bring non-prescription products, herbal remedies and supplements as well as prescribed medicines for review.

Confirm the first-week prescription and the instructions for day eight. A starter pack may contain different strengths for different days. Know how to reach the hospital urgently, including outside clinic hours, and arrange refills before your tablets run out.

How to take brigatinib

The first week and later doses

The usual starting schedule is 90 mg once daily for seven days, then 180 mg once daily if the team confirms it is appropriate. Do not start with the higher dose or increase early. In particular, new breathing symptoms during the first week must be assessed before any increase.

Alunbrig tablets are available in 30 mg, 90 mg and 180 mg strengths in the reviewed product information. Your tablet count therefore depends on the strength supplied. Check both the milligrams and the number of tablets whenever a prescription changes; do not use tablet colour or size as your only guide.

Take the medicine at a consistent time, with or without food, and swallow the tablets whole with water. Do not crush or chew them. If swallowing is difficult or a feeding tube is required, obtain a specialist pharmacist's plan instead of making a home-made mixture.

Missed doses, vomiting and interruptions

If you miss a dose, skip it and take the next dose at its scheduled time. Do not take an extra dose to catch up. If you vomit after taking brigatinib, do not replace that dose; take the next one when normally due. Repeated vomiting or difficulty keeping fluids down needs advice.

A longer interruption needs a new restart instruction. If treatment has been interrupted for 14 days or more for reasons other than side effects, the labels specify restarting at 90 mg daily for seven days before returning to the previously tolerated dose. This is a clinician-directed rule, not permission to restart yourself. A break because of toxicity follows the relevant safety rules and may require a lower dose or permanent stopping.

The labels advise against subsequently increasing a dose that was reduced because of side effects. Do not increase it when you feel better. An interaction-related adjustment is a different situation and also requires a new prescription when the interacting medicine changes.

If you accidentally take more than prescribed, contact your treating hospital immediately. Keep the pack and details of the dose and time available; do not wait for symptoms.

Storage and handling

Keep tablets in their original packaging, out of children's reach, protected from excessive heat and moisture. The US patient information specifies room-temperature storage at 20–25°C (68–77°F); European information does not require special storage conditions. Follow the instructions on the pack supplied to you, particularly during hot-weather travel. Return unwanted tablets through your hospital or pharmacy. Do not share them.

Monitoring and checking whether treatment is working

Blood pressure should be controlled before treatment. The US information specifies a check after two weeks and at least monthly afterwards. Extra checks may be needed if readings rise or medicines change. If you monitor at home, ask about technique, recording results and your own contact threshold. Symptoms and unusually high readings should not wait for the next appointment.

Pulse checks help detect bradycardia, meaning a slow heart rate. Tell the team about dizziness, faintness, unusual fatigue or near-blackouts. Some heart and blood-pressure medicines can also slow the pulse, so the complete medicine list matters. Do not stop those medicines independently.

Liver tests require close attention early on. European information specifies baseline testing and tests every two weeks during the first three months, then periodically. US information calls for regular monitoring, especially during those first three months. Follow your team's actual timetable.

CPK, amylase, lipase, fasting glucose and other blood results are checked regularly or periodically as appropriate. An abnormal result does not always mean symptoms or permanent damage, but it may require repeat tests, a pause or a dose change. Scans and clinical assessments answer the separate question of whether treatment is controlling the cancer.

Common side effects and practical care

Diarrhoea, nausea and constipation

Loose stools, nausea, vomiting and constipation can occur. Report a change from your usual bowel pattern, including how often it happens and whether there is pain. Use prescribed anti-sickness or anti-diarrhoea medicine as instructed. Frequent small drinks and manageable meals may help, with fluid advice adapted if you have heart or kidney restrictions.

Contact the team promptly for persistent diarrhoea, repeated vomiting, dizziness, reduced urine or inability to drink. Severe abdominal pain, blood in the stool or marked illness needs urgent assessment. Do not keep increasing over-the-counter bowel medicines without advice when warning symptoms are present.

For mild constipation, suitable fluids, activity and dietary changes may help. Ask about a laxative if needed. Constipation with vomiting, a swollen abdomen or severe pain needs assessment rather than simply more fibre.

Tiredness, headache and reduced appetite

Fatigue may affect work, concentration and daily tasks. Plan essential activities for better parts of the day and balance rest with gentle movement. A sudden deterioration, new breathlessness or faintness should be reported rather than attributed automatically to ordinary treatment fatigue.

Tell the team about persistent headache or poor appetite. Small meals may be easier than large ones, and dietetic support can help if weight is falling. Check pain medicines with your pharmacist. A severe unusual headache with confusion, weakness or visual symptoms is an emergency.

Rash, swelling and sensory changes

A rash or dry skin may respond to gentle washing and an unperfumed moisturiser. Ask before using medicated creams. Report a painful, widespread, blistering or rapidly worsening rash. Brigatinib can also make sunlight more damaging; the specific precautions are explained below.

Report new ankle, leg or facial swelling and rapid weight changes. Tingling or numbness can also occur and may affect balance or fine tasks. Describe these changes early so the team can assess their cause and help with symptoms. Swelling accompanied by sudden breathlessness needs urgent care.

Less common but important side effects

Lung inflammation, particularly early in treatment

Brigatinib can cause interstitial lung disease or pneumonitis: inflammation affecting the lungs. It can be serious and sometimes fatal. Some events begin within the first few days, which is why the first week needs particular vigilance. It can also occur later.

Contact the treating hospital immediately for new or worsening cough, breathlessness, wheeze or fever. Withhold further brigatinib while seeking immediate advice for these breathing symptoms. The team must assess the cause before you restart; infection, a clot and the cancer itself can cause similar problems. Severe breathing difficulty requires emergency care.

The team may arrange oxygen measurements, scans and other tests. Depending on the findings, treatment may be held, reduced or stopped permanently. Do not regard improvement overnight as permission to resume tablets or increase to the day-eight dose.

High blood pressure and slow heartbeat

High blood pressure may cause no symptoms, so scheduled measurements matter even when you feel well. Report troublesome headache, dizziness or blurred vision. Severe headache with neurological symptoms, chest pain or severe breathlessness requires emergency assessment. Your team may adjust blood-pressure treatment or brigatinib.

A slow heartbeat may cause weakness, light-headedness or fainting. Contact the team promptly for these changes; collapse or associated chest pain needs emergency help. A normal-looking blood-pressure result does not exclude a pulse problem.

Muscle, pancreatic and liver problems

Report unexplained muscle pain, tenderness or weakness, especially if substantial or worsening. A CPK rise may lead to a treatment interruption. Do not assume all muscle symptoms are due to exercise, and seek urgent advice if there is dark urine or marked weakness.

Raised amylase or lipase may be found on blood tests without symptoms. Persistent pain in the upper abdomen, particularly if it reaches the back or occurs with vomiting, needs urgent assessment for a pancreatic problem and other possible causes.

Liver changes may also be silent. Report yellowing of the eyes or skin, dark urine, pain on the right side of the upper abdomen, unusual bruising or pronounced loss of appetite. Blood-test results determine whether brigatinib can continue safely.

High blood sugar and visual changes

Blood glucose can rise whether or not you already have diabetes. Increased thirst, passing urine more often, blurred vision or unusual hunger should be reported. People with diabetes may need changes to their treatment. Vomiting, severe drowsiness, confusion or deep rapid breathing with suspected high glucose requires emergency assessment.

Report new blurred or double vision, light flashes, sensitivity to light or reduced vision promptly. You may need an eye specialist and a treatment pause. Do not drive with affected vision. Sudden loss of sight should be treated as an emergency rather than saved for the next clinic visit.

Sensitivity to sunlight

Photosensitivity is a recognised brigatinib risk, not just a general cancer-treatment precaution. Limit sun exposure throughout treatment and for at least five days after the last dose. Use shade, a hat and protective clothing, plus broad-spectrum UVA/UVB sunscreen and lip protection with SPF 30 or higher.

Report an unexpected sunburn-like reaction, pain or blistering. Severe reactions may require interruption or a dose change. Sunscreen does not make prolonged sun exposure safe. Keep these precautions in mind for commuting and ordinary outdoor activities as well as holidays.

Other medicines, supplements and vaccinations

Brigatinib interacts with medicines processed through an enzyme system called CYP3A. Some antibiotics, antifungals, antivirals and other medicines can raise its concentration; some seizure medicines, rifampicin and St John's wort can lower it. Avoid grapefruit and grapefruit juice because they can increase exposure. Taking an interacting product at a different time does not reliably solve the problem.

Strong CYP3A inhibitors and strong or moderate inducers should generally be avoided. If an interacting medicine is unavoidable, any adjustment must be prescribed, including when that medicine stops.

There is a meaningful regional difference: US instructions recommend avoiding moderate CYP3A inhibitors or reducing brigatinib if they cannot be avoided, whereas European information allows them with close monitoring without a routine dose reduction. Your specialist and pharmacist must choose the applicable plan. Do not calculate a dose change from an internet list.

Brigatinib may also reduce the effect of some other medicines, including hormonal contraception. Medicines that slow the pulse require particular review. Inform the pharmacist whenever a medicine is started, stopped or changed, even if another clinician prescribed it.

Discuss vaccines before receiving them, including travel vaccines. Whether a live vaccine is suitable depends on immune function and the complete treatment history; do not apply a generic post-treatment interval to yourself. Non-live vaccine timing can also be planned with the team.

Everyday life during treatment

Keep a simple record of tablets, symptoms and any home blood-pressure measurements. A reminder or support from a caregiver can help with the change between the first and second weeks. Arrange prescriptions and monitoring before travel, rather than interrupting treatment because tablets run out.

Gentle activity may help you maintain strength, but stop and seek advice for new breathlessness, faintness or muscle weakness. Do not drive or operate machinery when dizzy, unusually tired or visually affected. Ask about changes to work hours or tasks if concentration and energy vary.

Tell dentists and other healthcare professionals about brigatinib before procedures or new prescriptions. Discuss planned surgery with your cancer team; there is no universal self-directed pause supplied by this guide. Sex and intimacy can continue as comfortable, with the contraception precautions below. Support is available if treatment, uncertainty or symptoms affect mood, relationships or sleep.

Fertility, contraception, pregnancy and breastfeeding

Brigatinib can harm a developing baby. Contact your team immediately if pregnancy occurs or is suspected during treatment or the precaution period. Do not wait for the next planned review.

Female patients who could become pregnant need effective contraception during treatment and for at least four months after the final dose. European information specifically recommends effective non-hormonal contraception. Because brigatinib can reduce the reliability of hormonal methods, obtain specialist contraceptive advice rather than relying on a pill or implant without checking.

Male patients with female partners who could become pregnant should use effective contraception during treatment and for at least three months afterwards. The instructions are different for the person taking brigatinib who could become pregnant and for a male patient with a potentially pregnant partner; do not shorten either interval.

Do not breastfeed during treatment. US information continues this restriction for one week after the final dose; European information requires stopping during treatment without specifying the same post-dose interval. Confirm when feeding can safely restart, considering other medicines as well.

Animal findings suggest brigatinib may reduce male fertility; the effect in humans is uncertain. Discuss sperm preservation or other relevant fertility planning before treatment where possible. Reduced fertility is not reliable contraception.

After treatment finishes

Keep the follow-up appointments arranged for you. Blood pressure, glucose, liver results and other abnormalities may need continued monitoring until they settle. If medicines were added or adjusted during treatment, have them reviewed rather than stopping them yourself.

Continue sun precautions for at least five days and reproductive precautions for the stated periods. New breathing symptoms after treatment still need urgent assessment. Do not restart remaining tablets without a prescription, particularly after a long gap or a pause caused by side effects.

Frequently asked questions